{"_id": "65013acefddc0bb1312fb03c", "booleanRepresentation": "{\n    \"$and\": [\n        {\n            \"$and\": [\n                {\n                    \"$and\": [\n                        {\"$or\": [\n                            {\"$and\": [\n                                {\"$or\": [\n                                    {\"newly diagnosed stage IIIA non-small cell lung cancer (NSCLC)\"},\n                                    {\"newly diagnosed stage IIIB non-small cell lung cancer (NSCLC)\"},\n                                    {\"newly diagnosed stage IIIC non-small cell lung cancer (NSCLC)\"}\n                                ]},\n                                {\"unresectable\"},\n                                {\"histologically and/or cytologically confirmed\"}\n                            ]},\n                            {\"nodal recurrence after surgery for early stage NSCLC\"}\n                        ]},\n                        {\"Eastern Cooperative Oncology Group (ECOG) performance status\": {\"$in\": [0, 1]}}\n                    ]\n                },\n                {\"body weight\": {\"$gt\": 30}},\n                {\"unintentional weight loss\": {\"$lte\": 10}},\n                {\"baseline electrocardiography (ECG)\": {\"$lte\": 6}},\n                {\"measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1\": {\"$lte\": 4}},\n                {\"Absolute neutrophil count (ANC)\": {\"$gte\": 1500}},\n                {\"White blood cells (WBC) counts\": {\"$gte\": 2500}},\n                {\"Platelet count\": {\"$gte\": 100000}},\n                {\"Hemoglobin\": {\"$gte\": 9.0}},\n                {\"Total bilirubin\": {\"$lte\": 1.5}},\n                {\"Aspartate aminotransferase (AST) and alanine transaminase (ALT)\": {\"$lte\": 3.0}},\n                {\"Serum creatinine\": {\"$lte\": 1.5}},\n                {\"pulmonary function tests (PFTs) with both forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO)\": {\"$gte\": 40}},\n                {\"lung volume (V)20\": {\"$lte\": 35}},\n                {\n                    \"$or\": [\n                        {\n                            \"$and\": [\n                                {\"nodal recurrence after surgery for early-stage NSCLC\"},\n                                {\"No prior chemotherapy or radiation was ever administered for this lung cancer originally or for recurrence prior to entering this protocol\"},\n                                {\"Prior curative-intent surgery was at least 90 days prior to the nodal recurrence\"},\n                                {\"No prior radiation was administered to the region of study cancer that would cause overlap of treatment fields\"}\n                            ]\n                        },\n                        {\n                            \"$and\": [\n                                {\"human immunodeficiency virus (HIV) positive\"},\n                                {\"stable on their anti-retroviral regimen\"},\n                                {\"healthy from an HIV perspective\"},\n                                {\"CD4 count\": {\"$gt\": 250}},\n                                {\"not receiving prophylactic therapy for an opportunistic infection\"}\n                            ]\n                        },\n                        {\"prior or concurrent malignancy\": {\"$not\": {\"$or\": [\n                            {\"potential to interfere with the safety or efficacy assessment of the investigational regimen\"},\n                            {\"chemotherapy or radiotherapy within 4 weeks\"},\n                            {\"nitrosoureas or mitomycin C within 6 weeks\"}\n                        ]}}},\n                        {\"not pregnant or breast-feeding\"},\n                        {\"negative blood test or urine study\": {\"$lte\": 7}},\n                        {\"not expected to conceive or father children\": {\"$gte\": 1}},\n                        {\"not receiving non-protocol anti-cancer therapy after the end of Step 1 chemo/radiation or during Step 2 consolidation\"},\n                       ", "nctId": "NCT04092283", "title": "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC"}